This wiki has undergone a migration to Confluence found Here
2017-11-29 SGB Conference Call
Jump to navigation
Jump to search
back to Standards Governance Board main page
HL7 SGB Minutes |
Date: 2017-11-29 Time: 10:00 AM Eastern | ||
Facilitator | Paul/Calvin | Note taker(s) | Anne |
Attendee | Name
| ||
Regrets | Calvin Beebe | ||
Lorraine Constable | |||
Russ Hamm | |||
Tony Julian | |||
Paul Knapp | |||
Austin Kreisler | |||
Wayne Kubick | |||
Thom Kuhn | |||
Ken McCaslin | |||
Rik Smithies | |||
Sandy Stuart | |||
Quorum: Chair + 4 |
Agenda
- Agenda review
- Approve Minutes of 2017-11-15_SGB_Conference_Call
- Action Items
- Paul to ask Vocab to approve a motion that it was the WG’s intention in R3 for the Expansion profile to be balloted as STU. If PA has not documented approval, send them the same message
- Paul to verify with Karen that the documentation on the FHIR R3 ballot STU approvals is sufficient
- All: Further review of mixed ballot content precept on 2017-11-29 call
- Anne to add review of edited Product Life Cycle document to TSC agenda
- Complete; TSC ran out of time this week.
- Discussion Topics
- Review of definition of "Standards Under Review (SUR)" from the Standards Privacy Impact Assessment
- Mixed ballot precept
- Precept implementation strategy
- Backwards compatibility consistency and definition across families
- Parking Lot
- Review GOM with respect to where SGB and precepts should be reflected
- Review Publishing M&C updates regarding dual roles
- How do we deal with making sure that WGs involve those whose content domain they’re touching? (CIMI and Pharmacy and Lab models)
- Review Mission and Charter
- Handling situations where two documents come out of one project
- FHIR Product Director Position Description: we should 1) review further and draft feedback, then 2) map back the description to the role of FGB
- Drafting Shared Product Management Responsibilities
- Levels of standards
- Separation of concerns
- Ownership of content
- ISM
- Ask methodology groups to define how the definition of substantive change applies to their product family; management groups must then operationalize
Minutes
Meeting Outcomes
Actions
|
Next Meeting/Preliminary Agenda Items |
© 2017 Health Level Seven® International. All rights reserved